Radionetics Oncology entered strategic agreement with Eli Lilly under which Radionetics receives $140M upfront cash payment and Lilly obtains exclusive right to acquire Radionetics for $1B upon exercise. Deal builds on Lilly's radiopharmaceutical platform following 2023 POINT Biopharma acquisition. Top-25 pharma buyer.